Innate Pharma (ADR) (IPHA)
Develops innate-immunity-based antibody therapies for cancer alongside AstraZeneca and Sanofi collaborations.
$1.76
vs last close−0.04 (−2.22%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 0.20% | 192.4K ADS | |
|---|---|---|---|
| 10 holders · as of Jun 30, 2026 | |||
| Insiders | 16.68% | 15.66M ADS | |
| 2 holders · as of May 7, 2025 | |||
| Other | 83.12% | 78.05M ADS | |
| remainder | |||
93.90M ADS as of Sep 7, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
13F, as of Jun 30, 2026
10 holders · 192.4K shares · 3 new positions · 5 increased · 3 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Lion Point Capital, LP | 81.2K | 0.09% | 0 | Aug 14, 2026 |
| Morgan Stanley | 43.5K | 0.05% | 0 | Aug 13, 2026 |
| Smartharvest Portfolios, LLC | 23.8K | 0.03% | +23.8Knew | Aug 4, 2026 |
| XTX Topco Ltd | 15.1K | 0.02% | +15.1Knew | Aug 14, 2026 |
| Citadel Advisors LLC | 12.4K | 0.01% | +12.4Knew | Sep 2, 2026 |
| Jane Street Group, LLC | 10.3K | 0.01% | −33.1K | Aug 14, 2026 |
| Rhumbline Advisers | 4.7K | 0.01% | −15 | Aug 12, 2026 |
| UBS Group AG | 1.4K | 0.00% | +502 | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Sanofi | 9.05% | 8.35M | 13G | Apr 29, 2025 |
| MedImmune Limitedincl. AstraZeneca PLC | 8.30% | 7.83M | 13D | Feb 6, 2026 |
| Caisse des depots et consignationsincl. EPIC Bpifrance, CDC Croissance S.A. +2 more | 7.90% | 7.32M | 13D | May 7, 2025 |
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.